VIDEO: Proteomics International Laboratories Ltd (PIQLF) Interview with Managing Director Dr. Richard Lipscombe

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) Managing Director Dr. Richard Lipscombe is interviewed about the most recent Quarterly Report and the pipeline of precision diagnostic tests in commercialisation phase.

In the interview Dr. Lipscombe outlines the four leading tests the company has developed over a period of 25 years, and the progress the company is making with integrating these tests with key healthcare providers both in Australia and the USA.

In addition, the launch of mytest.health website provides a digital platform for the PromarkerD and PromarkerESO tests. PromarkerD is for early detection of Diabetic Kidney Disease, while PromarkerESO is a test for early detection of throat cancer.

With 2,100 collection sites in Australia, the pathway for the mitigation of serious medical costs associated with kidney disease from diabetes is now within reach of individuals. The tests are also now available through General Practitioners.

To View the Interview, please visit:
https://www.abnnewswire.net/lnk/6721MM96

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel 
Investor Relations and Corporate Advisor
Candour Advisory
T: +61 408 326 367 
E: dirk@candouradvisory.com.au

Matthew Wright
Media and Public Relations
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Proteomics International (Europe)
Plesmanweg 9, 7602 PD Almelo
The Netherlands
T: +31 85 40 11 173
E: Europe@PromarkerD.eu

News Provided by ABN Newswire